Dr. Karim Fizazi presented “Sequencing, Combination or Individualised Treatment?” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal, between October 14th and 16th, 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi, and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: sequencing, prostate cancer, combination
How to cite: Fizazi, Karim. “Sequencing, Combination or Individualised Treatment?” Grand Rounds in Urology. October 14-16, 2016. Accessed Feb 2026. https://grandroundsinurology.com/sequencing-combination-individualised-treatment
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal, between the 14th and 16th of October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi, and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Karim Fizazi, MD, PhD, is a medical oncologist at Centre Oscar Lambret and a Professor of Oncology at Paris-Saclay University in France. He is President of the French Group d’Etude des Tumeurs Genito-Urinaires (GETUG) at Institut Gustave Roussy, Vellejuif, France, and before moving to Centre Oscar Lambret, was the Head of the Department of Cancer Medicine there. Dr. Fizazi has served as President of the French Study Group of Carcinomas of Unknown Primary (GEFCAPI), serves as a Medical Advisor for the Mabqi Medical Advisory Board, and is a member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the American Association of Cancer Research (AACR).
Dr. Fizazi received his medical degree from the University of Poitiers in France and subsequently completed his residency in Paris. He completed a fellowship in medical oncology at Gustave Roussy, Villejuif, France, and spent 18 months in the United States at The University of Texas MD Anderson Cancer Center in Houston, Texas, where he researched bone metastases in prostate cancer. Dr. Fizazi went on to complete a PhD in cancer biology.
Dr. Fizazi has been involved in many Phase 1, 2, and 3 clinical trials as a national or global coordinating investigator. In 2014, he founded the Prostate Cancer Consortium in Europe (PEACE) to support clinical research at the European level, which oversees clinical trials designed to tailor treatment strategies to different patient profiles. The initial reports from these trials have been practice-changing. Dr. Fizazi is recognized as one of the world’s leading experts in testicular and prostate cancers. He has authored more than 500 scientific publications, and his work is regularly presented at major international conferences. He additionally serves as an Associate Editor with the European Journal of Cancer, a leading international scientific journal focused on oncology.
